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1 |  INTRODUCTION
Wolcott‐Rallison syndrome (WRS, OMIM 226980), first de-
scribed in 1972,1 is a rare form of neonatal diabetes caused 
by homozygous or compound heterozygous mutations in the 
EIF2AK3 gene. The gene encodes the enzyme protein kinase 
R‐like endoplasmic reticulum kinase (PERK) which is vital 
for the ability of cells to handle endoplasmic reticulum (ER) 
stress.2 Loss of function in PERK leads to apoptosis in situa-
tions of increased ER stress, resulting in permanent diabetes 
mellitus, multiple epiphyseal dysplasia, growth failure, and 
recurrent liver failure.3,4 Several other findings have been de-
scribed in association with WRS, among them primary hy-
pothyroidism, exocrine pancreas insufficiency, renal failure, 
neutropenia, anemia, central nervous system abnormalities, 
and developmental delay.5-8
Neonatal diabetes is, in most cases, the presenting symp-
tom. However, the phenotype is variable both with regard 
to organs involved and clinical severity. To this day, data 
on fewer than 100 children have been published, with most 
Received: 4 November 2018 | Revised: 16 February 2019 | Accepted: 8 April 2019
DOI: 10.1002/ccr3.2168  
C A S E  R E P O R T
Practical management in Wolcott‐Rallison syndrome with 
associated hypothyroidism, neutropenia, and recurrent liver 
failure: A case report
Markus Lundgren1,2  |   Elisa De Franco3 |   Henrik Arnell4,5 |   Björn Fischler4,5
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Arnell and Fischler contributed equally to this work.
1Department of Clinical Sciences, CRC 
Malmö, Lund University, Malmö, Sweden
2Department of Pediatrics, Kristianstad 
Central Hospital, Kristianstad, Sweden
3Institute of Biomedical & Clinical 
Science, University of Exeter, Exeter, UK
4Department of Pediatric Gastroenterology, 
Hepatology and Nutrition, Karolinska 
University Hospital, Stockholm, Sweden
5Division of Pediatrics, CLINTEC, 
Karolinska Institutet, Stockholm, Sweden
Correspondence
Markus Lundgren, Department of Clinical 
Sciences, Clinical Research Centre, Lund 
University, Jan Waldenströms gata 35, 205 
02 Malmö, Sweden.
Email: markus.lundgren@med.lu.se
Funding information
This research is supported in part by the 
Kristianstad Central Hospital Research and 
Development Fund, and the Skåne County 
Council Foundation for Research and 
Development. Genetic testing was funded 
by the Wellcome Trust.
Key Clinical Message
Wolcott‐Rallison syndrome is a rare genetic syndrome of neonatal diabetes, liver 
failure, and growth retardation. We present a case with a EIF2AK3 p.(Arg902Ter) 
mutation, additionally complicated by hypothyroidism, impaired renal function, and 
exocrine pancreas insufficiency, focusing on clinical management. For its optimiza-
tion, thorough care of multiple organ systems is needed.
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clinical centers only caring for a single patient. Morbidity, as 
well as mortality, is high among children with WRS.7,9
Here, we present the first published Swedish case of 
WRS complicated by recurrent severe liver dysfunction, 
neutropenia, and kidney dysfunction as well as primary hy-
pothyroidism and skeletal dysplasia. Our primary aim was 
to give a practical view and experience on management of a 
patient with WRS at a secondary pediatric center in southern 
Sweden.
2 |  CASE REPORT
The patient was born at 39 + 6 weeks with a birthweight 
of 2675g (−1.9 SDS) and birth length 47 cm (−1.6 SD) 
after an uncomplicated pregnancy. She was the first child 
of nonconsanguineous, healthy, parents of Albanian origin. 
There was no family history of diabetes or early deaths in 
the family. The patient was first admitted at 5 weeks of age 
with fever consistent with viral infection. At admission, 
she was hyperglycemic (blood glucose 41 mmol/L) but not 
in diabetes ketoacidosis (pH 7.35) and with an HbA1c of 
32 mmol/mol (5.5%). After initial treatment with intrave-
nous insulin (starting dose 0.025 U/(kg × h), she was put on 
an insulin pump (Medtronic Minimed®) with initial insulin 
requirement at discharge of 1.3 U/(kg × d). Bolus doses 
of regular 100 U/mL rapid‐acting insulin were determined 
using carbohydrate counting, where insulin to carbohydrate 
ratios were calculated by determining the blood glucose 
response to insulin and estimating the carbohydrate ratios 
accordingly. Blood glucose measurements in infancy were 
performed with finger pricks due to parental opposition to 
using continuous glucose (CGM) measurements. An ultra-
sound of the abdomen showed a pancreas and liver of nor-
mal size and appearance. Diabetes‐related autoantibodies 
(IAA, GADA, IA‐2A, and ZnT8A) were negative, and HLA 
genotyping revealed a genotype of DQA1*01‐DQB1*06, 
DQA1*05‐DQB1*0301 (HLA DQ6/7). Genetic testing for 
neonatal diabetes was performed by the Exeter Molecular 
Genetics laboratory using the previously published pipe-
line.10 Direct sequencing of the KCNJ11, INS, and ABCC8 
genes was performed by PCR followed by Sanger sequenc-
ing, but no likely pathogenic variant was identified. Testing 
of all other known neonatal diabetes genes, including 
EIF2AK3 (AF110146.1), was performed using a custom 
designed targeted next‐generation sequencing panel test, 
as previously described.11 The bioinformatics tools SIFT, 
PolyPhen‐2 and Align GVGD, were accessed through 
the ALAMUT Visual software version 2.7.1 (Interactive 
Biosoftware) to predict the effect of novel variants. The 
EIF2AK3 variant was confirmed by PCR and Sanger se-
quencing of exon 13 as a homozygous nonsense mutation 
(p.(Arg902Ter), c.2704C > T), previously described in 
WRS.9 Both parents were confirmed to be heterozygous 
carriers of the same mutation.
At 3 months of age, following the first vaccination 
against diphtheria, tetanus, and pertussis, she presented 
at the emergency room with lethargy, fever, hyperglyce-
mia, and dehydration. Initial laboratory analysis revealed 
a blood glucose level of 13.5 mmol/L, no acidosis (pH 
7.36), increased lactate (6.1 mmol/L), and markedly in-
creased liver function tests (LFTs) with AST 5900 U/L 
(ref. 20‐60 U/L) and ALT 4270 U/L (ref. 6‐50 U/L), ALP 
444 U/L (ref. 110‐320 U/L), total bilirubin of 30 µmol/L 
F I G U R E  1  Liver enzymes (AST 
(blue) and ALT (red)) during the patient's 
first (left panel) and most severe (right 
panel) exacerbations of liver dysfunction
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(ref. 3.4‐17 µmol/L), conjugated bilirubin 27 µmol/L, and 
a prothrombin time measured as INR of 1.5 (ref. 0.8‐1.2). 
Establishing venous access was difficult, and a central 
venous catheter was ultimately needed, which was later 
replaced by a subcutaneous venous port. During hospital-
ization, episodes of absences and suspected seizures en-
sued which lead to transfer to a tertiary regional center. 
An epilepsy work‐up was performed with a normal brain 
CT, normal EEG, and slightly increased protein levels 
in cerebrospinal fluid, consistent with blood‐brain bar-
rier damage. Eventually, she also developed neutropenia 
(0.7 × 109/L) which spontaneously normalized. The ini-
tial exacerbation of severe liver dysfunction subsided after 
10 days with complete biochemical resolution including 
LFTs and neutrophils (Figure 1).
Endocrine pancreatic function was assessed at first ad-
mission with a nonfasting c‐peptide level of 0.12 nmol/L 
(ref. for fasting sample: 0.37‐1.5 nmol/L). At repeat mea-
surements, c‐peptide was below the threshold of the analysis 
method. Fecal elastase, first analyzed after the age of one 
year, was repeatedly low around 70 µg/g (ref. >200 µg/g). 
Thyroid‐stimulating hormone was consistently elevated 
from one year of age (7‐11 mIE/L), with no thyroid autoanti-
bodies (TPO and TRAK) present, and levothyroxine therapy 
was initiated.
During the following 3.5 years, the patient suffered an 
additional six exacerbations requiring in‐patient care, all 
including severely elevated AST, ALT, and INR, and often 
neutropenia and compromised renal function. The most se-
vere exacerbation occurred at three years of age following an 
F I G U R E  2  Weight and length for age 
growth chart for 0‐24 months of age
Birth to 24 months: Girls
Length-for-age and Weight-for-age percentiles
Published by the Centers for Disease Control and Prevention, November 1, 2009
SOURCE:  WHO Child Growth Standards (http://www.who.int/childgrowth/en)
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uncomplicated viral infection. The patient was generally un-
well and admitted with elevated LFTs (AST 4100 U/L; ALT 
2215 U/L; INR normal on admission) (Figure 1). She had no 
ketoacidosis but was lethargic with decreased consciousness. 
During the coming days, she developed acute liver failure and 
was transferred to a pediatric hepatology and liver transplant 
unit to prepare for emergency liver transplant in case of ful-
minant progressive liver failure. At admission, at the tertiary 
center the patient displayed signs of grade 3 hepatic enceph-
alopathy (somnolence, confusion and gross disorientation). 
Liver enzymes reached a maximum ALT of 11.600 U/L, AST 
of 5.928 U/L with a maximum INR of 3.8 with a concur-
rent ammonia level of 91 µmol/L (ref. 11‐51 µmol/L). Her 
general well‐being and liver function rapidly improved after 
5 days of supportive therapy with antibiotics, lactulose, phy-
tomenadione, acetylcysteine, rifaximin, and nutritional sup-
plementation. However, as liver function improved, renal 
function deteriorated with increased serum levels of creat-
inine (245 µmol/L, ref. 22‐53 µmol/L), blood urea nitrogen 
(BUN; 17 mmol/L), and eventually anuria. Continuous he-
modialysis was initiated and continued for 8 days. The epi-
sode of renal failure was deemed likely to be caused by the 
exacerbation of WRS. Liver function tests subsequently re-
turned to normal although renal function remained slightly 
affected.
Two exacerbations of liver dysfunction and neutropenia 
temporally correlated with vaccination against diphtheria, 
tetanus, and pertussis (DTaP), administered at three and five 
months of age, respectively. After this, no other vaccinations 
were administered to the patient. The patient underwent 
anesthesia on several occasions, with no adverse events re-
corded. Sevoflurane, propofol, midazolam, rocuronium, at-
racurium, morphine, clonidine, and remifentanil were used, 
in standard dosing per kg. For pain and fever management, 
acetaminophen (paracetamol) was used, especially with in-
tercurrent liver enzyme elevation. The dosing was reduced 
at times of decreased liver synthetic function, as indicated 
by rising INR.
During the patients first years of life, the growth rate was 
normal, with no significant change in length and weight 
SDS. After an initial catch‐up following initiation of insulin 
therapy, she displayed a normal growth trajectory (Figure 
2). Initial x‐ray examination, at age 16 months, did not show 
any signs of epiphyseal dysplasia or osteopenia. However, 
when repeated at age 31 months clear signs of epiphyseal 
dysplasia were evident in metacarpals, carpals, radius, 
femur, tibia as well as possible metaphyseal dysplasia in 
carpal and metacarpal bones. At age 2.5 years, her length 
was 88.5 cm (−1.1 SDS; 14th percentile) and weight 13 kg 
(−0.64 SDS; 26th percentile). The patient reached her de-
velopmental milestones and showed no clear signs of devel-
opmental delay.
At three years of age, the patient was referred to a tertiary 
liver center for consideration for elective liver transplantation.
3 |  DISCUSSION
WRS is a rare autosomal recessive disorder with diverse phe-
notypic traits. Neonatal diabetes and epiphyseal dysplasia 
are considered consistent canonical features and can be ac-
companied by a variety of other manifestations. Dysfunction 
in several organ systems has been associated with the syn-
drome, and the pathogenesis is deemed to be caused by dys-
function of the PERK protein. This molecular defect leads to 
a decreased ability of the ER to handle protein folding during 
times of increased protein synthesis caused by increased de-
mands and stress. The accumulation of unfolded proteins in 
the ER results in an apoptosis signal and cell death leading to 
organ damage.2,12
Our patient is homozygous for a nonsense mutation in 
exon 13 of the EIF2AK3 gene (c.2704C > T, p.(Arg902Ter)) 
first described in 2009. To our knowledge, this is the fifth 
published case of WRS with the same mutation in children 
of Albanian descent.13 Unfortunately, clinical limited clini-
cal data are only published on two of these children. This 
additional published case further strengthens the hypothesis 
of a founder effect in this relatively small population. She 
was diagnosed with neonatal diabetes at five weeks of age. 
Glycemic control was complicated mostly by problems re-
lated to a diet heavy on infant formula, gruel, and porridge. 
She had no noticeable problems with hypoglycemia, aside 
from what is expected in insulin‐dependent diabetes. This 
contrasts with previous reports of problematic hyper‐ and hy-
poglycemia associated with WRS.6
The first episode of liver failure followed a routine vacci-
nation with DTaP at three months of age. Whether the ther-
apeutic attempts influenced the clinical course of this and 
the later episodes, or whether it was self‐limiting, remains 
unclear. At the present time, there is no published data sug-
gesting treatment choices in WRS which further compli-
cates treatment choices. That special care needs to be taken 
in conjunction with medications in patients with WRS has 
been reported previously (1,14). In our patient, however, only 
vaccinations were temporally associated with disease exac-
erbations, whereas all other medications were used without 
unexpected events. This may reflect the heterogeneity of the 
syndrome but may also highlight that the timing and setting 
of administration influence the potential side effects. In ad-
dition to liver dysfunction, a repeated pattern of moderately 
elevated serum levels of creatinine was found during exacer-
bations with a maximum reached at age three years where one 
exacerbation subsequently resulted in renal failure and the 
need for dialysis. Impaired renal function has been associated 
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with WRS in previous reports,9 although in contrast to ours 
described as a transient.
She was also diagnosed with primary hypothyroidism. This 
is in line with earlier reports proposing primary hypothyroidism 
as part of the phenotype in some patients with WRS14,15 and 
especially with the AF110146.1_p.(Arg902Ter) mutation pres-
ent in our patient and in previously published cases.13 Growth 
and developmental milestones were unremarkable in during the 
first 2.5 years. This is in contrast to previously published case 
reports where several patients have displayed faltering growth 
from approximately one year of age.7,16 Further follow‐up will 
clarify whether this positive trend will remain or whether falter-
ing growth will ensue with time.
4 |  CONCLUSION
Wolcott‐Rallison syndrome is an extremely rare and severe 
syndrome with highly variable clinical presentation where 
most patients are the only patient at their respective centers. 
Hence, each new patient is a challenge to the responsible phy-
sician, requiring a multi‐disciplinary approach. Careful and 
consistent evaluation of glycemic control, as well as renal, 
thyroid and pancreatic function and growth is needed. The 
patients are prone to repeated episodes of acute liver failure 
which may increase in severity with time with the subsequent 
risk of developing life‐threatening fulminant liver failure. 
Liver transplantation is an emerging concept, both as rescue 
treatment and as elective treatment, for patients with WRS 
as well as other metabolic diseases and may improve clinical 
outcomes.17,18
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